



Activity of Novel Antimicrobials against Gram-Negative Clinical Pathogens and Characterization of Their Resistance Mechanisms

Guest Editors:

Dr. Marco Coppi

1. Department of Experimental
and Clinical Medicine, University
of Florence, Florence, Italy
2. Microbiology and Virology Unit,
Florence Careggi University
Hospital, Florence, Italy

Dr. Chaitanya Tellapragada

Division of Clinical Microbiology,
Department of Laboratory
Medicine, Karolinska Institute,
Stockholm, Sweden

Deadline for manuscript
submissions:

closed (15 May 2024)

Message from the Guest Editors

Dear Colleagues,

In 2016, the World Health Organization enumerated a priority list of 12 species for which the discovery of new antibiotics was urgently required, including multidrug-resistant and carbapenem-resistant *Acinetobacter baumannii* and *Pseudomonas aeruginosa*, as well as carbapenem-resistant and/or third-generation cephalosporin-resistant *Enterobacteriaceae*. The combination of new β -lactams with old β -lactamase inhibitors (BLIs), or the establishment of antibiotics with new BLIs, is the most general approach adopted, followed by the modification of the chemical structure of old antibiotics. The aim of this Special Issue is to promote the dissemination of studies evaluating the activity of novel antimicrobial agents against local and nationwide collections of Gram-negative clinical isolates. Studies characterizing resistance mechanisms responsible for the reduced activity of novel drugs will be prioritized. Surveillance studies are of paramount importance to monitor the emergence of novel antibiotic resistance and to provide useful data for the implementation of infection prevention and control and antibiotic stewardship measures.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)